Serotonin and interleukin-6: the role of genetic polymorphisms in IFN-induced neuropsychiatric symptoms.
NAVINES, Ricard
University of Barcelona
Hospital del Mar Medical Research Institute [Barcelona, Spain] [IMIM]
Voir plus >
University of Barcelona
Hospital del Mar Medical Research Institute [Barcelona, Spain] [IMIM]
NAVINES, Ricard
University of Barcelona
Hospital del Mar Medical Research Institute [Barcelona, Spain] [IMIM]
University of Barcelona
Hospital del Mar Medical Research Institute [Barcelona, Spain] [IMIM]
GIMENEZ, Dolors
Universitat Autònoma de Barcelona = Autonomous University of Barcelona = Universidad Autónoma de Barcelona [UAB]
Universitat Autònoma de Barcelona = Autonomous University of Barcelona = Universidad Autónoma de Barcelona [UAB]
SOLA, Ricard
Universitat Autònoma de Barcelona = Autonomous University of Barcelona = Universidad Autónoma de Barcelona [UAB]
Universitat Autònoma de Barcelona = Autonomous University of Barcelona = Universidad Autónoma de Barcelona [UAB]
MARTIN-SANTOS, Rocio
University of Barcelona
Hospital del Mar Medical Research Institute [Barcelona, Spain] [IMIM]
< Réduire
University of Barcelona
Hospital del Mar Medical Research Institute [Barcelona, Spain] [IMIM]
Langue
EN
Article de revue
Ce document a été publié dans
Psychoneuroendocrinology. 2013-09-01, vol. 38, n° 9, p. 1803-13
Résumé en anglais
Cytokines and serotonin neurotransmission may play an important role on the development of psychopathological symptoms during interferon (IFN) treatment. The aim of the present study was to investigate the association ...Lire la suite >
Cytokines and serotonin neurotransmission may play an important role on the development of psychopathological symptoms during interferon (IFN) treatment. The aim of the present study was to investigate the association between IFN-induced depression, anxiety and fatigue and functional genetic variants at the interleukin-6 gene (IL-6) and serotonin transporter gene (SERT). 385 consecutive Caucasian outpatients with chronic hepatitis C initiating treatment with IFN-alpha and ribavirin were included. All patients were interviewed at baseline using the Structured Clinical Interview for DSM-IV (SCID-I) and those with a current major depressive disorder or anxiety disorder before starting treatment were excluded. Depression and anxiety were assessed at baseline during the treatment (at 4, 12, 24 and 48 weeks) using the Hospital Anxiety and Depression Scale and fatigue was evaluated using a visual analogue scale. The 5-HTTLPR region of SERT gene and the functional polymorphism located at the promoter region of IL-6 gene (rs1800795) were genotyped. Genotypic distribution was in the Hardy-Weinberg equilibrium for SERT (p=0.41) and for IL-6 (p=0.72) polymorphisms. At baseline we found only a significant effect of IL-6 polymorphism on fatigue symptoms. During antiviral treatment we reported that subjects with CC genotype (IL-6) presented significantly lower changes from baseline in IFN-induced depression (p=0.005) and IFN-induced anxiety (p=0.004). We did not find statistically significant differences on depression (p=0.21) or anxiety (p=0.15) between SS/SL and LL genotypes of SERT. Genetic variations in the IL-6 gene increase the risk of IFN-induced depression and anxiety. The IL-6 polymorphism was associated with fatigue rates in patients with chronic hepatitis C before treatment. Our study confirms the role of inflammatory mechanisms in IFN-induced psychopathological symptoms.< Réduire
Mots clés en anglais
Adult
Anti-Anxiety Agents
Antidepressive Agents
Antiviral Agents
Anxiety
Cohort Studies
Depression
Drug Therapy
Combination
Fatigue
Genetic Predisposition to Disease
Hepatitis C
Chronic
Humans
INDEL Mutation
Interferon-alpha
Interleukin-6
Middle Aged
Point Mutation
Polyethylene Glycols
Promoter Regions
Genetic
Prospective Studies
Recombinant Proteins
Ribavirin
Serotonin
Serotonin Plasma Membrane Transport Proteins
Whites
Unités de recherche